Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

Abstract Objective To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate c...

Full description

Bibliographic Details
Main Authors: Shotaro Nakanishi, Masato Goya, Mitsuyoshi Tamaki, Takuma Oshiro, Seiichi Saito
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Research Notes
Subjects:
mHSPC
Time to CRPC
Prostate cancer
3-Month %PSA
Online Access:https://doi.org/10.1186/s13104-021-05641-5

Similar Items

Similar Items